CANbridge Pharmaceuticals, Inc., a China-based global biopharmaceutical company committed to the research, development and commercialization of transformative rare disease and rare oncology therapies, announced...
Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, announced the completion of a CHF 15.5 million (EUR 15.2...
ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinical studies in the U.S....
